LGC, Biosearch Technologies today announces the release of three new product groupings to help the efforts of public health laboratories to detect the SARS-CoV-2 virus that causes COVID-19.
The Charité 2019-nCoV BHQ™/BBQ-650™ and US CDC 2019-nCoV ValuPanel™ Reagents are part of the ValuPanel line of detection reagents and are composed of probes and primers that resolve genetic signatures of different pathogen strains. Each oligonucleotide is delivered in separate, individual tubes for added flexibility where customers can pick and choose their signature of choice when running their assay.
Mark Dearden, VP of Strategy and Marketing at LGC, Biosearch Technologies, said, “LGC was one of the first companies to support the initial US public health response to COVID-19, partnering with the CDC to provide oligonucleotides used to support the CDC 2019-nCoV Real-Time PCR Diagnostic Panel. To build on this activity, we’re now also offering the Charité assay enabling anywhere from 1000 to 100,000 reactions per order and larger sizes of the US CDC 2019-nCoV assay for Research Use Only.”
“In today’s crisis, LGC’s core purpose of Science for a Safer World could not be more relevant and important. We are involved in many aspects of the global response, doing everything we can to accelerate delivery and scale our capacity and output in order to deliver these critical testing supplies and help meet our customers’ ramp their testing capability.”
LGC, Biosearch Technologies is dedicated in delivering quality, uncompromised probes and primers that are manufactured and shipped from a facility entirely separate from positive control production to protect the integrity of customers’ COVID-19 workflows.
LGC is the inventor of specific chemistries, such as Black Hole Quencher™ (BHQ™), BlackBerry™ Quencher (BBQ-650™) and other critical dyes and components for diagnostic kit developers. It has previously provided detection solutions for viruses including seasonal influenza, H1N1 (swine flu), Chikungunya, Zika, and Ebola.
In addition, LGC has CDC-qualified lots of SARS-CoV-2 probe and primer kits available for sale. Each kit contains enough material for 1,000 reactions, equivalent to 1,000 tests. Manufacturing capacity can build 1,000 kits per week, equivalent to 1,000,000 tests.